• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar

OINDPnews


H&T Presspart Low GWP Banner
  • Home
  • News
    • Business
    • Features
    • Medical
    • Regulatory
    • Products and Services
    • People
  • Events
  • Suppliers
    • Supplier listing and advertising options
    • Capsules and blisters
    • Consultants
    • Contract research
    • Contract manufacturing
    • Devices
    • Education
    • Excipients
      • Clinical Technology
    • Filling equipment
    • Instruments
    • Particle manufacturing
    • Software and modeling
  • Jobs
  • Resources
    • Webinars
    • White papers
  • LGWP Propellants
    • HFA 152a
    • HFO-1234ze(E)
    • LGWP Regulation
  • Contact

Galenica to provide GMP manufacturing for clinical trial supplies of Iconovo’s ICOone inhaler

DPI developer Iconovo has announced that Galenica AB will offer cGMP manufacturing of Iconovo’s ICOone single dose disposable DPI for clinical trials, so that customers wanting to develop an inhaled drug delivered by the ICOone device have an accelerated option for producing clinical trial supplies. According to the announcement, close cooperation between the companies, both of which are located in the Malmö-Lund region of Sweden, will allow customers to schedule manufacturing on short lead times.

As part of the collaboration, Galenica is installing and qualifying a manufacturing line for the ICOone inhaler and will be responsible for approving raw material suppliers. The new manufacturing line is expected to be ready in August 2022. Previously announced development projects using the ICOone DPI include a dry powder COVID-19 vaccine from Immune System Regulation (ISR) and Monash University’s inhaled oxytocin for the prevention of postpartum hemorrhage.

Iconovo CEO Johan Wäborg commented, “The collaboration with Galenica is part of our efforts to broaden the use of ICOone among international pharmaceutical companies developing novel medicines. We will have an even more attractive and complete customer offering by being able to provide our customers with a product ready to go into early clinical trials.”

Galenical CEO Ronnie Wallin said, “I’m happy that we can offer more customers our expertise in inhalation by collaborating with Iconovo. Through this close cooperation with Iconovo, the customer can quickly and seamlessly access world-class development in inhalation, which benefits the development of novel treatments that can help patients sooner.”

Read the Iconovo press release.

Share

published on May 3, 2022

Primary Sidebar

Sign up for our free weekly newsletter

Upcoming Events
Sponsored by Intertek

Want information about upcoming OINDP-related events delivered directly to your inbox? click here

  • June 17-June 18: Rescon Europe 2025, Paris, France
  • June 19-June 20: Metered Dose Inhaler (MDI) Technology Training Course, online
  • June 22-June 25: ISAM Congress 2025, Washington, DC, USA
  • June 25-June 25: SMI.London 2025, London, UK
  • September 18-September 19: IPAC-RS Nasal Innovation Forum, West Trenton, NJ, USA
  • See all upcoming events

    Secondary Sidebar

    Suppliers

    Capsules and blisters
    Consultants
    Contract research
    Contract manufacturing
    Devices
    Education
    Excipients
    Filling equipment
    Instruments
    Particle manufacturing
    Software and modeling
    Aptar Pharma banner
    © 2025 OINDPnews